Infusion of 5 mg/kg Infliximab + Infusion of 10 mg/kg Infliximab
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Pancreatitis
Conditions
Acute Pancreatitis
Trial Timeline
May 1, 2019 → Mar 31, 2027
NCT ID
NCT03684278About Infusion of 5 mg/kg Infliximab + Infusion of 10 mg/kg Infliximab
Infusion of 5 mg/kg Infliximab + Infusion of 10 mg/kg Infliximab is a phase 2 stage product being developed by Merck for Acute Pancreatitis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03684278. Target conditions include Acute Pancreatitis.
What happened to similar drugs?
20 of 20 similar drugs in Acute Pancreatitis were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03684278 | Phase 2 | Recruiting |
Competing Products
20 competing products in Acute Pancreatitis